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Background-—Patients with hypertension are primarily treated in general practice. However, major studies of patients with
hypertension are rarely based on populations from primary care. Knowledge of blood pressure (BP) control rates in patients with
diabetes and/or cardiovascular diseases (CVDs), who have additional comorbidities, is lacking. We aimed to investigate the
association of comorbidities with BP control using a large cohort of hypertensive patients from primary care practices.
Methods and Results-—Using the Danish General Practice Database, we included 37 651 patients with hypertension from 231
general practices in Denmark. Recommended BP control was deﬁned as BP <140/90 mm Hg in general and <130/80 mm Hg in
patients with diabetes. The overall control rate was 33.2% (95% CI: 32.7 to 33.7). Only 16.5% (95% CI: 15.8 to 17.3) of patients with
diabetes achieved BP control, whereas control rates ranged from 42.9% to 51.4% for patients with ischemic heart diseases or
cerebrovascular or peripheral vascular diseases. A diagnosis of cardiac heart failure in addition to diabetes and/or CVD was
associated with higher BP control rates, compared with men and women having only diabetes and/or CVD. A diagnosis of asthma
in addition to diabetes and CVD was associated with higher BP control rates in men.
Conclusion-—In Danish general practice, only 1 of 3 patients diagnosed with hypertension had a BP below target. BP control rates
differ substantially within comorbidities. Other serious comorbidities in addition to diabetes and/or CVD were not associated
with lower BP control rates; on the contrary, in some cases the BP control rates were higher when the patient was diagnosed
with other serious comorbidities in addition to diabetes and/or CVD. ( J Am Heart Assoc. 2012;2:e004531 doi: 10.1161/
JAHA.112.004531)
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H ypertension is a common disorder with an estimatedprevalence of 22% to 27% worldwide, and it is an
important risk factor for cardiovascular disease (CVD) such as
stroke and myocardial infarction.1–4 Patients with hyperten-
sion are primarily treated in general practice, making it the
most frequent reason for consultations with general practi-
tioners (GPs).5,6 However, major studies of patients with
hypertension are rarely based on populations from primary
care. The importance of treating patients with hypertension to
target blood pressure (BP) levels applies to patients with and
without comorbidities. For example, patients with CVD have
an increased risk of recurrent stroke or myocardial infarction
if their BP is above recommended levels.7–11 Only a few
studies exist on the prevalence of hypertension and rates of
BP control among patients with CVD; these studies are mainly
based on small selected populations7,12–14 or are not situated
in primary care populations.12–15 In Europe, BP control rates
in hypertensive patients range from 21% to 57%.2,16–18 The BP
control rates are generally based on mixed populations of
patients with and without comorbidities. Furthermore,
patients with a chronic disease like hypertension often have
1 or more additional chronic comorbidity,7 and when patients
have 2 or more comorbidities, the treatment of each of the
comorbidities is generally poorer,19–23 which further affects a
patient’s chance of achieving BP control. To our knowledge, it
has not been investigated how additional comorbidities are
associated with BP control when patients already have
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diabetes and/or CVD. In this article, we aimed to analyze the
association of comorbidities with BP control in a large cohort
of hypertensive patients from primary care.
Methods
Study Design
From November 1, 2009, to January 31, 2011, we used the
Danish General Practice Database (DAMD) to include 37 651
hypertensive patients from a sample of 231 general practices
equally distributed across Denmark. From Statistics Denmark,
we retrieved information about redeemed prescriptions, com-
orbidities, and number of contacts with the healthcare system.
Danish Health Care
The healthcare system in Denmark is tax funded, providing
universal access to general practice and hospital care for all
inhabitants, regardless of age and geographic residence. A total
of 98% of the 5.5 million Danish citizens are registered with a
GP. There are 2100 general practices in Denmark represent-
ing 3780 GPs. Each GP has on average 1470 registered
patients. The GPs are “gate-keepers” for further contacts with
the secondary healthcare system. Reimbursement for prescrip-
tion medication increases with patient expenses.24
Guidelines for Hypertension
GPs in Denmark have guidelines for BP measurement
recommending that ofﬁce BP should be measured at least
twice with patients sitting down after 5 minutes of rest using
a cuff properly adapted to the arm size. A maximum of a
5 mm Hg difference between the 2 last measurements is
acceptable, and the mean of these 2 measurements is used
for clinical decisions.25,26 The treatment goals are evidence
based and recommended for patients up to the age of
80 years (BP below 140/90 mm Hg in general and <130/
80 mm Hg in patients with diabetes).25 With home BP
measurements, guidelines recommend BP <135/85 mm Hg
in general and <130/80 mm Hg in patients with diabetes.
Data Sources and Measurements
Danish General Practice Database
All inhabitants in Denmark can be identiﬁed by a unique civil
registration number, allowing individual linkage across a vast
number of registers. The DAMD contains information related
to individual consultations with a GP.27,28 It uses a data
capture module incorporated in the GP’s information
technology system. The data capture module automatically
sends information on prescribed medication, diagnoses,
disbursement codes, and laboratory data to DAMD for each
contact with a patient. Diagnoses at contacts are coded
according to the International Classiﬁcation of Primary Care
(ICPC) system (second edition).29 From each contact, we
retrieved diagnoses, prescribed medication, and laboratory
results including BP. By April 2012, a total of 52% of all
practices in Denmark were registered in DAMD. A national
agreement states that by April 2013, all 2100 practices in
Denmark are obliged to use the data capture module and
consequently contribute data to DAMD.
Statistics Denmark
The Danish Register of Medical Product Statistics contains all
prescriptions since 1995 with patient identiﬁer, date, and drug
(anatomical therapeutic chemical [ATC] code). The Danish
National Patient Register has information about admissions,
outpatient services, and emergency department contacts
with Danish hospitals since 1994 classiﬁed according to
the International Classiﬁcation of Diseases, Tenth Revision. The
Danish Health Register has information on all contacts to the
healthcare system since 1990.
Participants
Our study population was identiﬁed based on the following
criteria: Patients were included if they had a consultation with
their GP during the study period and if the reason for
encounter was hypertension (ICPC diagnosis: K86; uncompli-
cated hypertension, K87; complicated hypertension) or if they
were prescribed antihypertensive medication and the GP
speciﬁcally wrote that the medication was BP-lowering (ATC
code C02-C04; C06-C09). These criteria indentiﬁed 83 190
patients with hypertension (Figure 1). In addition, patients
had to be alive during the entire study period and registered
with the same GP. Because treatment goals are recom-
mended for patients up to the age of 80 years, patients
<25 years and ≥80 years were excluded (11 118 patients). A
total of 9383 patients had no registered BP measurement
within the study period. An additional 24 968 patients had no
BP measurement registered in DAMD. The ﬁnal study
population therefore consisted of 37 651 patients with
hypertension from 231 practices (representing 415 GPs).
BP, index date, and time periods
The ﬁrst BP measurement registered within the study period
was used for analyses of BP control. The date of this
measurement for each patient was deﬁned as the index date.
If 2 BP measurements were registered at the same index date,
the mean of these was used for additional analyses. If there
were >2 measurements, the mean of the 2 lowest mea-
surements was used. Information from DAMD consisted of
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individual patient data 12 months before the index date.
Information from the Danish National Patient Register and the
Danish Register of Medical Product Statistics was available
15 yearsand14 years before apatient’s indexdate, respectively.
Antihypertensive drug treatment
Antihypertensive drug treatment included diuretics, angioten-
sin-converting enzyme inhibitors (ACEIs), angiotensin II
receptor blockers (ARBs), calcium channel blockers,
b-blockers, and other antihypertensive agents. To measure
adherence, prescriptions redeemed before a patient’s index
date were used according to the following principle: 1 tablet
covered a 1-day supply (allowing for 20% nonadherence; eg,
redemption of 100 tablets corresponded to 120 tablets). If a
redeemed prescription provided a patient with enough tablets
available to cover their index date, the patient was deﬁned as
being adherent to the redeemed drug. Combination drugs
were split into each drug class. Patients were categorized as
being adherent to treatment with 0, 1, 2, 3, or ≥4 drugs. The
duration of antihypertensive treatment was categorized as
follows: no prior prescription redeemed, 0 to 1 year, 1 to
2 years, 2 to 5 years, 5 to 10 years, or ≥10 years, based on
the time interval between the index date and the ﬁrst
redemption of an antihypertensive drug prescription. We used
DAMD to determine whether a GP had prescribed antihyper-
tensive drugs to a patient.
Comorbidity
We deﬁned patients as having diabetes based on a diagnosis
of diabetes in DAMD or in the Danish National Patient
Register or as having receiving prescribed or redeemed blood
glucose–lowering drugs in the registers. From the Danish
National Patient Register, we further extracted diagnoses for
the following diseases: CVDs, ischemic heart diseases (IHDs),
peripheral vascular diseases (PVDs), and other serious
comorbidities (congestive heart failure [CHF], atrial ﬁbrillation,
Figure 1. Flowchart. ICPC indicates International Classiﬁcation of Primary Care; BP, blood pressure; DAMD, Danish General Practice Database.
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chronic obstructive pulmony disease [COPD], osteoporosis,
asthma, cancer, and psychiatric diseases).
Statistical Analysis
The primary outcome measure is optimal BP control. Due to
interaction between sex and age (P<0.001) and sex and CVD/
diabetes comorbidities (P=0.0003) in relation to BP control,
we stratiﬁed all tables and analyses according to sex. Patients
were categorized as being diagnosed with either “no diabetes
or CVD,” “CVD,” “diabetes,” or “diabetes plus CVD.” Means
are presented with SDs in Table 1 and with 95% CIs around
the means in Table 2. We used logistic regression to analyze
the association between BP control and various covariates. All
regression analyses were adjusted for cluster effect at
practice level using robust cluster estimation. Odds ratios
(ORs) are presented with 95% CIs. A value of P<.05 was
considered statistically signiﬁcant. We performed sensitivity
analyses of BP control. In the ﬁrst analysis, we used the
lowest BP measurement instead of the mean of the 2 lowest
measurements. In the second sensitivity analysis, we hypoth-
esized that 57.4% of the 24 968 excluded patients (Figure 1)
had achieved BP control. The 57.4% rate corresponds to
control rates found in the most recent Danish study on
hypertension.2 STATA release 12.0 (StataCorp, College Sta-
tion, TX) was used for all statistical analyses.
Ethics
The study was approved by DAMD (10/09), the Danish Data
Protection Agency (2009-41-4204), and the National Institute
of Public Health (7-604-04-2/139). The study did not need
approval by the Regional Ethics Committee (http://www.
dnvk.dk/CVK/Home/English.aspx).
Results
Of the 37 651 patients included, 50.7% were women. Their
meanSD age was 63.310.3 years. A total of 22 595
patients (60.0%) were included due to a diagnosis of
hypertension and the remaining 15 056 (40.0%) were
included due to prescribed antihypertensive medication. Of
those included due to a diagnosis of hypertension, 76.9%
were prescribed antihypertensive drug treatment by their GP.
Table 1 presents the baseline characteristics. More men than
women were diagnosed with CVD (24.3% versus 14.0%) and
with diabetes (30.8% versus 21.6%). The majority of patients
(87.3%) had been treated for hypertension for >1 year and
63.4% had been treated for ≥5 years. A total of 6.1% had not
redeemed a prescription for antihypertensive drugs during the
past 14 years (Table 1).
BP Control
The BP control rate for all 37 651 patients was 33.2% (95% CI:
32.7 to 33.7) (Table 1). Patients <40 years old had a control
rate at 33.3%, whereas control rates in the other age groups
were 40 to 49 years (29.9%), 50 to 59 years (32.3%), 60 to
69 years (33.5%), and 70 to 79 years (34.5%), respectively. For
patients without diabetes 39% had a BP <140/90 mm Hg,
whereas 59% had a BP <145/95 mm Hg (Figure 2).
BP Control in Patients With Diabetes and CVD
In 9843 patients with diabetes an overall BP control rate of
16.5% (95% CI: 15.8 to 17.3) was achieved. A total of 50% of
patients with diabetes had a BP <140/90 mm Hg, and 67%
had BP <145/95 mm Hg (Figure 2). Table 2 presents BP
control rates in patients with comorbidities. In patients with
diabetes but without CVD, 14.7% (95% CI: 13.9 to 15.5)
achieved BP control, whereas patients with diabetes and CVD
had a higher control rate (22.3%; 95% CI: 20.6 to 23.9)
(Table 2). The BP control rate for patients with CVD, but
without diabetes, was 47.4% (95% CI: 46.0 to 48.9). Within
cerebrovascular disease, myocardial infarction, and PVD, BP
control rates ranged from 42.9% to 51.4% (Table 2).
BP Control Within Other Serious Comorbidities
Patients diagnosed with congestive heart failure had the
highest control rate at 47.1% (95% CI: 44.5 to 49.6), whereas
patients having asthma or a psychiatric disease had the
lowest at 33.8% (95% CI: 30.9 to 36.7) or 35.0% (95% CI: 33.0
to 37.0), respectively (Table 2). Generally, BP control rates did
not differ much between sexes, except in patients diagnosed
with osteoporosis (women: 36.6%, men: 47.4%) (Table 2).
OR for BP Control in Patients With Diabetes
and/or CVD
Women with CVD had higher odds of BP control (OR: 1.19
[95% CI: 1.09 to 1.31]) compared with women without
diabetes or CVD (Table 3). However, women with diabetes
(OR: 0.26 [95% CI: 0.23 to 0.30]) and women with diabetes
plus CVD (OR: 0.35 [95% CI: 0.28 to 0.42]) had decreased
odds of BP control (Table 3). The same statistically signiﬁcant
tendencies were seen for men, with OR for BP control at 1.39
(CVD), 0.26 (diabetes), and 0.40 (diabetes plus CVD),
respectively, compared with men without diabetes or CVD
(Table 3). CHF or atrial ﬁbrillation was associated with higher
odds of BP control for both men and women, whereas COPD
only was associated with higher odds of BP control in men
(OR: 1.25 [95% CI: 1.06 to 1.48]).
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Table 1. Characteristics of 37 651 Patients With Hypertension From Primary Care: BP, Treatment, and Comorbidities
No. of Patients Women* Men* All*
Participants 37 651 50.7 (n=19 107) 49.3 (n=18 544) 100 (n=37 651)
Age, mean y (SD) 37 651 63.6 (10.5) 62.9 (10.2) 63.3 (10.3)
BP, mm Hg
Ofﬁce systolic BP, mean (SD) 37 651 140.5 (17.4) 141.1 (17.3) 140.8 (17.4)
Ofﬁce diastolic BP, mean (SD) 37 651 83.0 (10.7) 83.9 (11.1) 83.4 (10.9)
BP control 37 651 35.7 30.6 33.2
Duration of antihypertensive treatment
No prescription redeemed 2304 5.1 7.2 6.1
0 to 1 year 2493 5.9 7.4 6.6
1 to 2 years 2140 5.2 6.2 5.7
2 to 5 years 6865 16.0 20.6 18.2
5 to 10 years 9405 24.2 25.8 25.0
≥10 years 14 444 43.7 32.8 38.4
Adherence to antihypertensive treatment†
0 drugs 4923 12.5 13.7 13.1
1 drug 10 947 30.1 28.0 29.1
2 drugs 12 149 34.2 30.3 32.3
3 drugs 7351 18.3 20.8 18.5
≥4 drugs 2281 5.0 7.2 6.1
Comorbidity
Diabetes‡ 9843 21.6 30.8 26.2
Diabetes§ 7428 17.5 22.0 19.7
Diabetes plus CVD‖ 2415 4.1 8.8 6.4
CVD‡¶ 7170 14.0 24.3 19.0
Cerebrovascular disease‡ 3155 7.0 9.8 8.4
IHD‡ 3734 6.0 13.9 9.9
PVD‡ 1452 2.9 4.8 3.9
Other serious comorbidities‡ 9677 25.8 25.6 25.7
COPD 1610 4.5 4.1 4.3
Psychiatric diseases 2215 5.3 6.5 5.9
Asthma 1030 3.4 2.1 2.7
Osteoporosis 802 3.6 0.6 2.1
Cancer 3151 9.1 7.6 8.4
Congestive heart failure 1441 2.7 4.9 3.8
Atrial ﬁbrillation 2251 4.2 7.8 5.6
BP indicates blood pressure; CVD, cardiovascular disease, IHD, ischemic heart disease; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; GP, general
practitioner; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
*Percent, unless otherwise indicated as mean (SD) in ﬁrst column.
†Number of antihypertensive drugs within the following: diuretics, ACEIs, ARBs, b-blockers, or calcium channel blockers.
‡Diagnosis of the disease, regardless of the presence of other diseases.
§Patients diagnosed with diabetes but without CVD. Patients could have a diagnosis of other serious comorbidities.
‖Patients diagnosed with diabetes and CVD. Patients could have a diagnosis of other serious comorbidities.
¶CVD includes cerebrovascular diseases, ISHs, and PVDs, where some patients have more than one of the diseases.
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Patients Diagnosed With Serious Comorbidities in
Addition to Diabetes and/or CVD
Table 4 present the proportions of patients with BP control for
patients with various additional comorbidities, stratiﬁed on sex
and diabetes and/or CVD comorbidities. If men with diabetes
(BP control: 12.8%) had a further diagnosis of any of the other
serious comorbidities, a higher proportion of patients achieved
BP control. Examples were men with diabetes and COPD
(BP control: 19.3%) and men with diabetes and atrial ﬁbrillation
(BP control: 17.4%). The same tendencies were seen for men
having CVD and for men having diabetes and CVD (Table 4). A
higher proportion of women achieved BP control if they had a
diagnosis of COPD, CHF, and atrial ﬁbrillation in addition to a
Table 2. BP Level and Control in Patients With and Without Comorbidities
Women Men All
BP control (%)*
No comorbidity 39.5 32.4 37.0
Category for diabetes/CVD comorbidity†
No CVD or diabetes‡ 40.0 33.9 37.4
CVD‡ 46.6 48.0 47.4
Diabetes 16.0 13.5 14.7
Diabetes plus CVD‡ 21.5 22.6 22.3
CVD without diabetes‡
Cerebrovascular disease 45.1 46.1 45.6
IHD 49.8 51.4 50.9
PVD 42.9 45.6 44.4
Other serious comorbidities§
COPD 38.0 39.7 38.8
Psychiatric disease 38.1 35.3 35.0
Asthma 35.1 34.2 33.8
Osteoporosis 36.6 47.4 38.2
Cancer 34.8 35.8 35.2
Congestive heart failure 45.2 48.1 47.1
Atrial ﬁbrillation 43.6 40.1 41.4
BP levels, mean (95% CI)
Category for diabetes/CVD comorbidity†
No CVD or diabetes‡ 141.1 (141.1 to 141.7) 143.5 (143.1 to 143.8) 142.3 (142.1 to 142.5)
CVD‡ 139.2 (138.4 to 140.0) 138.0 (137.3 to 138.6) 138.5 (138.0 to 139.0)
Diabetes 138.3 (137.8 to 138.9) 139.6 (139.1 to 140.1) 139.0 (138.7 to 139.4)
Diabetes plus CVD‡ 137.0 (135.7 to 138.2) 135.9 (135.0 to 136.7) 136.2 (135.5 to 136.9)
BP indicates blood pressure; CVD, cardiovascular disease; IHD, ischemic heart disease; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease.
*BP control: BP <140/90 mm Hg in general and BP <130/80 mm Hg in patients diagnosed with diabetes.
†In the category for diabetes/CVD comorbidities, a patient was categorized as being diagnosed with either “no CVD or diabetes,” “CVD,” “diabetes,” or “diabetes plus CVD” regardless of
the presence of other serious comorbidities.
‡CVD includes cerebrovascular diseases, IHDs, and PVDs, where some patients have more than one of the diseases.
§Diagnosis of the disease, regardless of the presence of other diseases.
Figure 2. Proportion of patients with a blood pressure (BP) below
the speciﬁed BP level.
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diagnosis of diabetes and/or CVD (Table 4). However, in
women diagnosed with CVD (BP control: 46.4%) a lower
proportion achieved BP control, if they had one of the additional
comorbidities psychiatric disease, asthma, osteoporosis, or
cancer (Table 4). Table 5 shows the ORs of BP control for
various additional comorbidities, stratiﬁed on sex and diabe-
tes/CVD comorbidity. We found that a diagnosis of CHF in
addition to diabetes and/or CVD was associated with higher
odds of BP control for both men and women. A diagnosis of
asthma in addition to diabetes and CVD was associated with
higher odds of BP control in men. For both men and women,
having a diagnosis of other serious comorbidities were never
signiﬁcantly associated with lower odds of BP control, if the
patients also had diabetes and/or CVD (Table 5).
Sensitivity Analysis
In the ﬁrst sensitivity analysis of BP control using the lowest
BP measurement, overall BP control rates changed from
33.2% to 35.7%, and in patients with diabetes from 16.5% to
18.2%. In the second sensitivity analysis, where 57.4% of the
24 968 excluded patients were assumed to have achieved BP
control, the estimated overall BP control rate would have
increased to 42.8% if the 24 968 excluded patients had been
included for analyses in the study population.
Discussion
This study showed that only 33.2% of patients with hyperten-
sion treated in primary care inDenmark achieved BP control and
that the BP control rate varied considerably between patients
with comorbidities. Other serious comorbidities in addition to
diabetes and/or CVD was not associated with lower odds of BP
control, on the contrary, in some cases the odds of BP control
were higher, when diagnosed with other serious comorbidities
in addition to diabetes and/or CVD.
BP Control
The low BP control rate found in our study is worrying, especially
in patients with the highest need of BP control such as patients
with diabetes or previous myocardial infarction or stroke.
Although patients with CVD have a higher BP control rate than
the overall study population, their control rates are still
inadequate, because their risk of recurrent stroke ormyocardial
infarction increaseswith BP above recommended limits.3,7,10,12
However, raising the BP limit to 145/95 mm Hg increases the
overall BPcontrol rate from39.1% to58.7%, indicating thatmany
patients are close to target BP levels (Figure 2, patients without
diabetes). Some of this difference may be caused by “end-digit
preference,”which occurswhenGPs round values up or down to
Table 3. OR for the Association Between BP Control and Comorbidities in 37 651 Patients
Speciﬁc Comorbidities
Adjusted for Age*
Adjusted for Age, Treatment, Duration,
and Serious Comorbidities† Adjusted for Age*
Adjusted for Age, Treatment,
and Serious Comorbidities†
Women Men
Category for diabetes/CVD comorbidity‡
No CVD or diabetes 1.00 1.00 1.00 1.00
CVD 1.35 (1.23 to 1.48)‖ 1.19 (1.09 to 1.31)‖ 1.65 (1.51 to 1.82)‖ 1.39 (1.26 to 1.53)‖
Diabetes 0.29 (0.25 to 0.32)‖ 0.26 (0.23 to 0.30)‖ 0.30 (0.26 to 0.34)‖ 0.26 (0.23 to 0.30)‖
Diabetes plus CVD 0.42 (0.35 to 0.51)‖ 0.35 (0.29 to 0.42)‖ 0.52 (0.44 to 0.61)‖ 0.40 (0.33 to 0.48)‖
Serious comorbidities
COPD 1.13 (0.96 to 1.34) 1.09 (0.92 to 1.31) 1.39 (1.20 to 1.61)‖ 1.25 (1.06 to 1.48)¶
Psychiatric disease 1.11 (0.95 to 1.29) 1.14 (0.97 to 1.35) 1.13 (0.99 to 1.29) 1.06 (0.93 to 1.21)
Asthma 0.90 (0.77 to 1.05) 0.90 (0.77 to 1.06) 1.19 (0.96 to 1.47) 1.03 (0.81 to 1.31)
Osteoporosis 1.08 (0.92 to 1.27) 0.97 (0.81 to 1.14) 1.87 (1.33 to 2.62)‖ 1.39 (0.98 to 1.99)
Cancer 0.98 (0.87 to 1.10) 0.97 (0.85 to 1.11) 1.15 (1.04 to 1.28)¶ 1.07 (0.96 to 1.19)
Congestive heart failure 1.57 (1.30 to 1.90)‖ 1.54 (1.24 to 1.90)‖ 2.04 (1.80 to 2.32)‖ 1.90 (1.63 to 2.20)‖
Atrial ﬁbrillation 1.49 (1.28 to 1.72)‖ 1.34 (1.15 to 1.56)‖ 1.44 (1.30 to 1.60)‖ 1.19 (1.06 to 1.33)¶
CVD indicates cardiovascular disease; COPD, chronic obstructive pulmonary disease; OR, odds ratio; BP, blood pressure.
*OR for the association between optimal BP control and each covariate, adjusted for age. ORs are presented with 95% CI.
†OR for the association between optimal BP control and CVD comorbidities adjusted for age, treatment (number of antihypertensive drugs), and each of the other serious comorbidities
(asthma, COPD, cancer, osteoporosis, psychiatric diseases, atrial ﬁbrillation, and congestive heart failure). ORs are presented with 95% CI.
‡In the category for diabetes/CVD comorbidities, a patient was categorized as being diagnosed with either “no CVD or diabetes,” “CVD,” “diabetes,” or “diabetes plus CVD.”
§P<0.05.
‖P<0.001.
¶P<0.01.
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multiplesof5or10.30–32 It could alsobedue to reluctanceby the
GP to intensify treatmentwhenBP is close to target, for example,
acceptingasystolic valueof145 mm Hg,which is slightly above
BP goal.33–36 A GP could have a resistance toward further
medication due to lack of belief in additional BP-lowering effect
by adding a third or fourth antihypertensive drug. The patient
Table 4. Blood Pressure Control According to Comorbidities, Stratiﬁed on Sex, Diabetes, and/or CVD (Proportion of Patients With
Blood Pressure Control—37 651 Patients)
Category for Diabetes/CVD Comorbidity*
No Diabetes or CVD
(n=23 053) Diabetes (n=7428) CVD (n=4755)
Diabetes Plus CVD
(n=2415)
Women Men Women Men Women Men Women Men
No other serious comorbidities† 39.9 33.4 15.1 12.8 46.4 44.6 21.7 17.7
Other serious comorbidities
COPD 42.0 42.0 20.1 19.3 49.7 55.5 23.2 36.1
Psychiatric disease 44.9 33.1 18.8 14.5 42.7 51.2 26.3 26.8
Asthma 38.3 35.6 14.8 15.2 44.7 46.4 25.0 43.6
Osteoporosis 38.7 43.4 13.4 33.3 43.7 59.5 29.0 45.5
Cancer 39.6 40.8 18.1 16.7 42.6 47.9 17.0 25.7
Congestive heart failure 52.8 53.2 35.4 23.6 56.0 67.3 26.3 35.4
Atrial ﬁbrillation 53.2 46.3 23.9 17.4 47.5 55.7 24.2 28.3
CVD indicates cardiovascular disease; COPD, chronic obstructive pulmonary disease.
*In the category for CVD comorbidities, a patient was categorized as being diagnosed with either “no CVD or diabetes,” “CVD,” “diabetes,” or “diabetes plus CVD.”
†Other serious comorbidities include asthma, COPD, cancer, osteoporosis, psychiatric diseases, atrial ﬁbrillation, and congestive heart failure.
Table 5. Odds Ratio for BP Control—Stratiﬁed on Sex, Diabetes, and/or CVD
Category for Diabetes/CVD Comorbidity* No Diabetes or CVD† (n=23 053) Diabetes† (n=7428) CVD† (n=4755) Diabetes Plus CVD† (n=2415)
Women n=13 090 n=3345 n=1887 n=785
COPD 1.08 (0.88 to 1.31) 1.33 (0.90 to 1.98) 1.16 (0.84 to 1.61) 1.16 (0.84 to 1.62)
Psychiatric disease 1.23 (1.00 to 1.53) 1.27 (0.86 to 1.86) 0.86 (0.62 to 1.19) 1.29 (0.78 to 2.15)
Asthma 0.93 (0.76 to 1.13) 0.92 (0.54 to 1.55) 0.96 (0.62 to 1.49) 1.24 (0.56 to 2.75)
Osteoporosis 0.98 (0.81 to 1.18) 0.83 (0.40 to 1.68) 0.91 (0.63 to 1.31) 1.45 (0.73 to 2.86)
Cancer 0.99 (0.84 to 1.15) 1.19 (0.90 to 1.57) 0.86 (0.64 to 1.15) 0.74 (0.41 to 1.32)
Congestive heart failure 1.63 (1.18 to 2.25)‖ 2.87 (1.82 to 4.54)¶ 1.49 (1.05 to 2.11)§ 1.31 (0.86 to 2.01)
Atrial ﬁbrillation 1.63 (1.35 to 1.95)¶ 1.64 (1.09 to 2.47)§ 1.05 (0.73 to 1.49) 1.22 (0.74 to 2.02)
Men n=9963 n=4083 n=2868 n=1630
COPD 1.23 (0.97 to 1.55) 1.43 (0.96 to 2.15) 1.39 (1.04 to 1.85)§ 1.84 (1.28 to 2.65)
Psychiatric disease 0.99 (0.83 to 1.18) 1.17 (0.82 to 1.66) 1.16 (0.91 to 1.49) 1.35 (0.92 to 1.99)
Asthma 1.06 (0.79 to 1.42) 1.14 (0.60 to 2.17) 0.95 (0.59 to 1.51) 2.72 (1.40 to 5.30)‖
Osteoporosis 1.17 (0.72 to 1.89) 2.96 (1.06 to 8.33) 1.60 (0.82 to 3.11) 2.87 (0.88 to 9.38)
Cancer 1.15 (1.00 to 1.32) 1.15 (0.82 to 1.62) 0.94 (0.74 to 1.19) 1.13 (0.73 to 1.75)
Congestive heart failure 1.77 (1.32 to 2.37)¶ 1.91 (1.24 to 2.93)‖ 2.29 (1.74 to 3.01)¶ 2.01 (1.54 to 2.61)‖
Atrial ﬁbrillation 1.36 (1.15 to 1.60)¶ 1.27 (0.87 to 1.84) 1.38 (1.12 to 1.71)‖ 1.22 (0.88 to 1.70)
CVD indicates cardiovascular disease; COPD, chronic obstructive pulmonary disease; BP, blood pressure.
*In the category for CVD comorbidities, a patient was categorized as being diagnosed with either “no CVD or diabetes,” “CVD,” “diabetes,” or “diabetes plus CVD.”
†For each category of CVD comorbidities and for each sex, we used logistic regression to calculate the odds ratio for BP control adjusted for age, treatment (number of antihypertensive
drugs), duration of antihypertensive drug treatment, and each of the other serious comorbidities (asthma, COPD, cancer, osteoporosis, psychiatric diseases, atrial ﬁbrillation, and
congestive heart failure).
§P<0.05.
‖P<0.01.
¶P<0.001.
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might also resist further medication such as being treated with
>5 different types of medications, which is not uncommon for
patients with comorbidities.
Similar to other studies, we found that patients with diabetes
have a much lower degree of BP control than the general
population of patients with hypertension.12,17,18,37,38 The BP
targets of BP<130/80 mm Hg inpatientswith diabetesmaybe
more difﬁcult to reach thanBP limits<140/90 mm Hg,which is
conﬁrmed by the fact that 50% of all diabetics reached a BP
<140/90 mm Hg (Figure 2). TheBPcontrol rate of 16.5%might
even have been overestimated, because guidelines recommend
that patients with diabetes and nephropathy should have a BP
<120/80 mm Hg.25 Nephropathy is in general practice in
Denmarkmeasured throughmicroalbuminuria,whichwedidnot
have information on. Furthermore, the ICPC system differenti-
ates between diabetes type 1 and type 2 but not between
diabetes with or without microalbuminuria. Hence, it was not
possible to identify patients with diabetes and nephropathy and
this could have overestimated their control rate. If patients with
diabetes have BP limits below the general BP limits of 140/
90 mm Hg,otherprioritiesmight inﬂuence theeffort to lowerBP
down to the recommended 130/80 mm Hg. If a patient’s BP
was very high when treatment was started, it might be that a
reduction of the BP to levels >130/80 mm Hg is considered
acceptable.33,34 It is also possible that someGPs consider 140/
90 mm Hg “close enough to target” or perhaps have a different
perception of acceptable BP levels in patients with 2, 3, or more
comorbidities. Because guidelines in Denmark and other
countries are unambiguous, we need studies investigating
barriers from GPs in their management of patients with
hypertension.
Comparison of BP Control Within Studies
We found that 33.2% of our study population achieved BP
control. In a study by Gu et al,15 much higher control rates
were found (women: 44.8%, men: 51.8%) in hypertensive
patients from primary care. The proportion of patients with
diabetes in their study was, however, much lower than in our
study (men: 13.7%, women: 15.4%). In other studies of
prevalence and control of hypertension, the proportion of
patients with CVD and diabetes were even lower.2,39 Our
study showed that comorbidity is an important aspect to
consider because BP control rates range from 14.7% (diabetes
without CVD) to 50.9% (IHD). Cautions are therefore in place
regarding comparisons of BP control rates between studies
with particular attention to comorbidity. For the organization
of treatment and control of hypertension in primary care, the
different BP control rates related to comorbidities are also
important. Identifying patients whose BP is difﬁcult to control
may direct focus to the patients with the greatest need of
attention. Our study population of hypertensive patients is
included from general practices, which already have a data
capture module installed in their medical information tech-
nology system. The data capture module provides the GPs
with quality reports by which the GPs can identify their own
hypertensive patients with and without comorbidities and with
and without BP control. The extent to which GPs in these
practices use the quality reports to improve treatment and
control of hypertension is not yet investigated.
Additional Comorbidities
Men diagnosed with asthma in addition to diabetes and CVD
had higher odds of BP control compared with men having
diabetes and CVD. This should be considered together with
the fact that a patient with asthma needs treatment with
b2-agonist (bronchodilator) in periods with exacerbations.
Asthma patients are therefore extra sensitive to treatment
with b-blocking agents for hypertension, because their
asthma might become worse. Another side effect of
b-blocking agents is a rise in blood glucose levels in patients
with diabetes, which may complicate the regulation of their
diabetes. This illustrates that treating hypertensive patients
with asthma, diabetes, and CVD is a major challenge and the
fact that these patients had improved BP control is remark-
able. Other serious comorbidities in addition to diabetes and/
or CVD were not associated with statistical signiﬁcantly lower
odds of BP control. We believe that this could be due to the
fact that patients with additional comorbidities have a higher
frequency of contacts to their GPs than patients with no
additional comorbidities. Although most comorbidity-related
consultations may not be planned for hypertension control
with BP measurement, the frequent contacts to the GP may
lead to a closer monitoring of BP, to better communication
between GP and patient, to agreement on BP targets, and to
an agreement on prevention of additional diseases.40 Fur-
thermore, in Denmark, the GPs are responsible for treating
almost all diseases and the GPs can therefore tailor a
treatment strategy, taking all aspects of different diseases
into consideration. Another reason for higher BP control rates
in patients with additional comorbidities could be that
patients with, for example, atrial ﬁbrillation or CHF are
treated with medications for their disease, which also lower
their BP level. Patients with CHF in addition to diabetes and/
or CVD were found to have a much higher degree of BP
control in our study, which could be due to the tendency to
falling BP in patients with CHF. In Denmark, there has been
increased focus on the treatment of patients with psychiatric
diseases and their comorbidities. It is generally considered
that comorbidities in psychiatric patients are not treated
adequately. Studies has furthermore reported that adherence
to antihypertensive drug treatment in psychiatric patients is
low, which inﬂuences a patient’s ability to achieve BP
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control.20,41 However, hypertensive patients diagnosed with
psychiatric diseases were not associated with lower BP
control rate, if a patients had a psychiatric diseases in
addition to diabetes and/or CVD. This may also be a
consequence of psychiatric patients more frequent contact
to their GPs. BP control rates in different comorbidities
depends on many factors, hereby the medical treatments and
the nature of each disease, which are complex interactions
and will affect the patient’s ability to achieve BP control.
Strengths and Limitations
A main strength of this study is the inclusion of a large cohort
of >37 000 patients with hypertension from primary care with
no selection bias in relation to comorbidities and socioeco-
nomic status. Furthermore, the inclusion did not depend on
voluntary participation. A limitation is that we lack information
on how the patients’ BP was measured. However, the cross-
sectional design with inclusion of only one BP measurement
was speciﬁcally chosen to resemble the “real world” of clinical
practice, presenting a realistic picture of the hypertensive
population as it is managed daily in primary care. The majority
of patients (87.3%) had been treated with antihypertensive
drugs for at least 1 year and their included BP measurement
was presumably used to support the GPs in clinical decisions.
The 6.1% of our study population who had not redeemed any
prior prescriptions for antihypertensive drugs (Table 1) may
be newly diagnosed with hypertension, be receiving nonphar-
macological treatment, or be nonadherent for the past
15 years. Their BP levels have probably not reached target
levels yet, because their regulation and intensifying of
treatment are in an initial phase. The overall BP control rate
only changed from 33.2% to 35.7% in the ﬁrst sensitivity
analysis using the lowest BP measurement instead of the
mean of the 2 lowest measurements. Had we used a patient’s
last BP measurement registered in the study period, instead
of the ﬁrst BP measurement, it would have caused method-
ological problems: Patients included in the beginning of the
study period would then have a longer observation time to
improve their BP control compared with patients included at
Table 6. Characteristics of the 37 651 Hypertensive Patients Included Compared With the 24 968 Excluded Patients Without a
Blood Pressure Measurement Registered
Characteristics Included Patients (%)† Excluded Patients (%)†
N 37 651 24 968
Age, y*
<40 931 (2.5) 758 (3.0)
40 to 49 3561 (9.5) 2825 (11.3)
50 to 59 8093 (21.5) 5899 (23.6)
60 to 69 14 083 (37.4) 9075 (36.4)
70 to 79 10 975 (29.2) 6411 (25.7)
Mean age, y (SD) 63.3 (10.3) 62.1 (10.4)
Sex
Women 19 107 (50.8) 12 884 (51.6)
Men 18 544 (49.2) 12 084 (48.4)
Deﬁned as hypertensive due to
A diagnosis of hypertension 22 595 (60.0) 7069 (28.3)
Prescribed antihypertensive medication 15 056 (40.0) 17 899 (71.7)
Prescribed antihypertensive medication by their GP within the past year* 30 400 (80.7) 23 335 (93.5)
Contact with GP*
No. of contacts with GP/y 9.63 7.69
Telephone contacts 2.73 2.67
Diagnosis of diabetes in DAMD* 9353 (24.8) 1870 (7.5)
BP indicates blood pressure; GP, general practitioner; DAMD, Danish General Practice Database.
*Number of contacts/year, age, prescribed antihypertensive medication by their GP, and a diagnosis of diabetes in DAMD were all measured according to a patient’s index date. We had
1 year before a patient’s index date available to investigate each covariate.
†For the included group of patients, their index date was the date of their ﬁrst BP measurement present in DAMD. Because the 24 968 excluded patients had no BP measurement
registered, we deﬁned their index date to be the ﬁrst date present of either a consultation with their GP or the date of prescribed antihypertensive medication, whichever were present ﬁrst
in our study period (November 1, 2009 to January 31, 2011).
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the end of the study period. By using the patient’s ﬁrst BP
measurement, all patients have the same observations time to
contribute a BP measurement. We excluded 24 968 patients
from our study population because they had no BP measure-
ment registered in DAMD (Figure 1, Table 6). The excluded
24 968 patients had the same distribution of age and sex as
patients included in the study (Tables 1 and 6). However,
fewer of the excluded patients had a diagnosis of diabetes.
Depending on the procedures in each practice, some of the
24 968 patients could have had a BP measurement written in
the medical records, which was not transferred to DAMD
using the data capture module. Due to lower comorbidity
rates, BP may not have been measured in the excluded
patients, because they attended their GP for reasons other
than hypertension. If 57.4% of all 24 968 patients achieved
BP control, the sensitivity analysis showed that BP control
rates increased from 33.2% to 42.8% if the excluded patients
had been included in the study. Although this BP control rate
is more acceptable, there is still room for improvement.
Generalizability
We included 84% of all patients with hypertension from our
sample of 231 practices, assuming the true prevalence of
hypertension is 25.7% and awareness of hypertension is 63.5%
according to the most recent study of prevalence of hyper-
tension in Denmark.2 One of our inclusion criteria was that
patients had to attend their GP within a period of 15 months.
Some patients attend their GP with longer time intervals, for
example, every second or third year, probably because they
have better BP control or no comorbidities. Had we extended
our inclusion period and included patients attending their GP
with wider time intervals, our BP control rate for patients
without comorbidities might have been a little higher.
Implications for Practice and Further Research
Further research should investigate differences in GPs’ man-
agement of patients with and without comorbidities, and
differences in patients’ understanding and acceptance of
treatment and control of hypertension with relation to comor-
bidities. Furthermore, it would be useful with more research
targeting GPs’ use of quality improvement reports in general
and whether the use of these could lead to improvement in
treatment and control of hypertensive patients.
Conclusion
In Danish general practice only 1 of 3 patients diagnosed with
hypertension had a BP below target. BP control rates differ
substantially within comorbidities. BP control was poorer
among patients with diabetes, whereas CVD in particular was
associated with improved BP control. Other serious comorbid-
ities in addition to diabetes and/or CVD was not associated
with lower BP control rates; on the contrary, in some cases the
BP control rates were higher, when diagnosed with other
serious comorbidities in addition to diabetes and/or CVD.
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